Original Investigation

Cost-Effectiveness of Alcohol Use Disorder Treatment for Alcohol-Associated Liver Disease

JAMA Network Open 10.1001/jamanetworkopen.2026.44980

November 18, 2026 at 11:00 AM EST

Read the full article

In this economic evaluation of AUD treatment for patients with ALD, treating patients with ALD with naltrexone and CBI at F3 saved cost and was more effective than no treatment, reducing progression to compensated and decompensated cirrhosis. The results remained true at stages F1 and F2 fibrosis and when considering the societal costs and the costs of AUD. Future studies should include prospective evaluations of screening strategies combined with early treatment, as many patients are diagnosed at advanced stages of ALD.

Corresponding Author: Chin Hur, MD, MPH, Department of Medicine, Columbia University Irving Medical Center, 622 W 168th St, New York, NY 10032 (chin.hur@columbia.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.44980

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks